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Gentamicin accumulates in the lysosomes of kidney proximal tubular cells and causes apoptosis at clinically
relevant doses. Gentamicin-induced apoptosis can be reproduced with cultured renal cells, but only at high
extracellular concentrations (1 to 3 mM; 0.4 to 1.2 g/liter) because of its low level of uptake. We recently showed
that gentamicin-induced apoptosis in LLC-PK1 cells involves a rapid (2-h) permeabilization of lysosomes and
activation of the mitochondrial pathway of apoptosis (10 h). We now examine whether the delivery of genta-
micin to the cytosol by electroporation would sensitize LLC-PK1 cells to apoptosis. Cells were subjected to eight
pulses (1 ms) at 800 V/cm (square waves) in the presence of gentamicin (3 M to 3 mM; 1.2 mg/liter to 1.2
g/liter); returned to gentamicin-free medium; and examined at 8 h for their Bax (a marker of mitochondrial
pathway activation) contents by Western blotting and competitive reverse transcriptase PCR and at 24 h for
apoptosis by 4,6-diamidino-2-phenylindole staining (conﬁrmed by electron microscopy) and for necrosis (by
determination of lactate dehydrogenase release). Nonelectroporated cells were incubated with gentamicin for
8 and 24 h. Signiﬁcant increases in Bax levels (8 h) and apoptosis (24 h) were detected with 0.03 mM (13.2
mg/liter) gentamicin in electroporated cells compared with those achieved with 2 mM (928 mg/liter) in
incubated cells. The increase in the Bax level was not associated with an increase in the level of its mRNA but
was associated with the accumulation of ubiquitinated forms (probably as a result of impairment of its
degradation by the proteasome). Assay of cell-associated gentamicin showed a marked, immediate, but tran-
sient accumulation in electroporated cells, whereas a slow, steady uptake was detected in incubated cells. The
data indicate that cytosolic gentamicin triggers apoptosis. Sequestration of gentamicin in lysosomes would, to
some extent, protect against apoptosis.
Aminoglycoside antibiotics have long been known to cause
acute renal failure in patients, in association with histological
and functional signs of proximal tubule toxicity (1). Yet, the
underlying molecular mechanisms still remain poorly deﬁned
(15). Aminoglycosides enter proximal tubular cells by pinocy-
tosis from the luminal pole and accumulate in lysosomes (18,
27, 62), where they cause a conspicuous phospholipidosis (29,
32). Maneuvers that prevent gentamicin pinocytic uptake (59)
and/or the development of lysosomal phospholipidosis (28)
protect against nephrotoxicity. Together with the fact that the
corresponding morphological and biochemical alterations de-
velop early on in animals or humans treated with clinically
relevant doses (10, 32), this was the main argument that linked
aminoglycoside cell toxicity to its lysosomal storage and the
ensuing organelle dysfunction (40). Gentamicin, indeed, is a
highly polar compound and is therefore largely considered to
be unable to pass across membranes and to act outside of
lysosomes. Besides lysosomal changes, however, the proximal
tubules of animals treated with gentamicin also show clear
signs of apoptosis (11, 34). This effect of gentamicin, together
with the lysosomal alterations described above, can be repro-
duced in vitro with both renal and nonrenal cells (2, 12). These,
however, must be exposed to high concentrations of gentami-
cin because of poorly efﬁcient drug uptake (12). Using LLC-
PK1 cells, an accepted model of renal proximal tubular cells for
the study of aminoglycoside toxicity (24, 64, 66, 67, 72), we
observed that gentamicin causes an early permeabilization of
lysosomes before activation of the mitochondrial pathway of
apoptosis can be detected (61). In parallel, recent data indicate
that a minor but probably signiﬁcant proportion of the genta-
micin accumulated by cells can reach the cytosol and the mi-
tochondria by trafﬁcking through the Golgi apparatus and the
endoplasmic reticulum (56). We also know that apoptosis can
be triggered in the kidney by cytosolic signals, such as an
increase in the cytosolic Bax protein content, which activates
the so-called mitochondrial pathway of apoptosis (54). This has
raised the question whether it is not the cytosolic gentamicin
that is released from or transported out of lysosomes that
triggers apoptosis. This has now been tested directly by taking
advantage of the technique of electroporation, which allows
the direct delivery of membrane-impermeant solutes into cells
(14). Our results show that LLC-PK1 cells undergo extensive
apoptosis when they are subjected to electroporation in the
presence of concentrations of gentamicin about 100-fold lower
than what is necessary if cells are incubated with the drug. We
also show that this process is associated with an increase in the
cell content of the proapoptogenic protein Bax, which acts
upstream of the mitochondria in the cascade that leads to
apoptosis (71). The data therefore imply that the lysosomal
sequestration of gentamicin could actually protect cells from
its apoptogenic effect and thereby mitigate its toxicity.
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Cells. All experiments were performed with LLC-PK1 (Lilly Laboratories
Culture-pig kidney) cells, clone ATCC CL-101, that originated from and that
displayed the attributes of proximal tubular cells (60). They were cultivated in
Dubelcco’s modiﬁed Eagle’s medium supplemented with 10% fetal calf serum in
an atmosphere of 95% air–5% CO2; subcultured twice a week; and used at about
80% conﬂuence to avoid cell detachment, which spontaneously takes place after
the cells reach conﬂuence. Cells grown under these conditions are not polarized
and, in contrast to LLC-PK1 cells grown on inserts to trigger their polarization
(47), do not express megalin (17), a protein that causes receptor-mediated
endocytosis of gentamicin in renal tubular cells in vivo (42). Previous studies
showed that gentamicin is taken up by ﬂuid endocytosis in LLC-PK1 cells (i.e.,
without evidence of membrane binding) under our conditions of culture (12).
Electroporation. We follow the general technique developed for delivery of
membrane-impermeant drugs in mammalian cells (14, 26, 53). In brief, subcon-
ﬂuent cells were detached by trypsinization (5 g/liter trypsin, 2 g/liter sodium
EDTA, 8. g/liter NaCl), centrifuged at 1,000 rpm (5810 R centrifuge equipped
with an A-4-62 rotor; Eppendorf AG, Hamburg, Germany), and resuspended in
electroporation buffer (10 mM Na2HPO4/KH2PO4, pH 7.2, 250 mM sucrose, 1
mM MgCl2) in the presence of a suitable concentration of gentamicin (0 to 3
mM). One hundred microliters of cell suspension (roughly corresponding to 50
g of cell protein) was placed in electroporation cuvettes (model 620; BTX-
Genetronics Inc., San Diego, CA) made of two embedded aluminum electrodes
2 mm apart. The cells were exposed to 8 square-wave pulses (PA-4000 device;
Cyto Pulse Sciences, Inc., Columbia, MD) with an electric ﬁeld of 800 V/cm for
1 ms (with a 1-Hz repetition frequency) and were thereafter left for 15 min at
room temperature in the same medium. They were then dispersed in 5 ml of
gentamicin-free, complete culture medium and transferred into cell culture
dishes for incubation at 37°C for up to 24 h. These conditions were selected
based on preliminary pilot studies that assessed the efﬁciency of the cell pene-
tration of two nonpermeant tracers (trypan blue and lucifer yellow) compared
with the release of the cytosolic enzyme lactate dehydrogenase (as a marker of
cell membrane leakage). For the sake of conciseness, cells treated according to
this protocol are consistently referred to as “electroporated.”
Incubation. The cells were continuously exposed to gentamicin at 37°C in
complete cell culture medium at the indicated concentrations and for the indi-
cated times. Cells treated according to this protocol are consistently referred to
as “incubated.”
Detection of apoptosis and necrosis. Apoptotic cells were enumerated after
they were stained with 4,6-diamidine-2-phenylindole (DAPI) to reveal the char-
acteristic nuclear changes of apoptosis (condensation and fragmentation of the
nuclear material), as described earlier (61). Necrosis was assessed by measuring the
amount of the lactate dehydrogenase activity released in the medium (43).
Measurement of gentamicin cell content. Cells were collected by scrapping
them into ice-cold phosphate-buffered saline (PBS) after three successive washes
with the same buffer and were subjected to brief sonication. Gentamicin was then
assayed by a disk-plate microbiological technique using Bacillus subtilis (ATCC
6633) as the test organism, as described previously (12, 68). Our routine assay
had a limit of detection of 0.1 mg/liter, with a range of linearity up to 64 mg/liter
(R
2  0.994  0.005 [n  6]). The protein content of the samples was measured
by the Folin-Ciocalteu method (38). All gentamicin cell contents were expressed
as g/mg cell protein. The apparent cellular gentamicin concentration was then
calculated based on a cell volume of 5 l per mg protein (68). In previous studies,
we showed that samples from control cells spiked with amounts of gentamicin
similar to those detected here in electroporated or incubated cells gave readings
within 90% of the expected values.
Detection of Bax and ubiquitinated Bax. The cells were washed three times
with ice-cold PBS and resuspended in lysis buffer (10 mM N-2-hydroxyethyl
piperazine-N-2-ethane sulfonic acid [HEPES], 2 mM EDTA, 0.1% 3-[(3-chol-
amidopropyl) dimethyl-ammonio]-1-propane sulfonate [CHAPS], 5 mM 1,4-di-
thiothreitol [DTT]) supplemented with protease inhibitors (1 mM phenylmethyl-
sulfonyl ﬂuoride [PMSF], 10 g/ml pepstatin A, 10 g/ml aprotinin, 20 g/ml
leupeptin). The samples were then subjected to ﬁve successive cycles of freezing-
thawing (dry ice, acetone, 37°C water bath) and centrifuged at 12,000 rpm for 20
min (Eppendorf 5415C centrifuge). The supernatants were collected, and 10 g
of protein (as measured by a modiﬁed Bradford method [51]) was mixed with
Laemmli buffer for detection of Bax by Western blot analysis, as described
previously (61), and by use of a rabbit anti-Bax antibody raised against a synthetic
peptide corresponding to amino acids 44 to 62 of human Bax (1:500; Calbiochem
Immunochemicals catalog no. 196821; Merck KGaA, Darmstadt, Germany) and
peroxidase-labeled anti-rabbit immunoglobulin G (IgG). Bands were revealed by
using the SuperSignal West Pico chemiluminescence substrate (Pierce, Rock-
ford, IL). The ﬁlms were scanned with a commercial ﬂatbed digitizer operated at
a resolution of 600 dpi, and the images were subjected to densitometric analysis
for the bands corresponding to the monomer of Bax (21 kDa [48]) by using
Image J software (version 1.3.1; available from the Research Service Branch of
the National Institute of Mental Health [http://rsb.info.nih.gov/ij]). For detection
of ubiquitinated Bax, the lysis buffer was supplemented with 1 mg/liter ubiquitin
aldehyde and 10 M Z-Leu-Leu-Leu-aldehyde (MG132; an inhibitor of the
proteasome) and protease inhibitors (pepstatin, aprotinin, leupeptin). Fifty mi-
crograms of protein was then immunoprecipitated by addition of 3 l of undi-
luted anti-Bax antibody, followed by an overnight incubation at 4°C in a total
volume of 1 ml. The mixture was then mixed with 30 l protein A-agarose beads
f o r2ha t4 ° Ca n dcentrifuged at 12,500 rpm (Eppendorf 5415C centrifuge) for
5 min at 4°C. The pellets were washed twice with ice-cold lysis buffer, once in 0.5
M NaCl, and once with PBS and were ﬁnally resuspended in Laemmli buffer for
Western blot analysis. Ubiquitinated proteins were identiﬁed by incubating the
membranes for 24 h at 4°C with a mouse monoclonal antibody (FK2; 1:1,000)
directed against ubiquitinated proteins (but not free ubiquitin) and obtained
from Biomol International LP, Plymouth, PA. Visualization was obtained with
peroxidase-labeled anti-mouse IgG, and the bands were revealed and quantiﬁed
as described above by using the 47- to 55-kDa region corresponding to the
ubiquitinated forms of Bax (35, 50).
Quantitative measurement of Bax mRNA. We used the competitive reverse
transcriptase PCR (RT-PCR) technique using an internal standard (7). RNA was
extracted by using the TRIzol reagent (Life Technologies, Gaithersburg, MD)
and treated with 0.8 kU of DNase I (QIAGEN GmbH, Hilden, Germany) for 15
min at room temperature. The RNA was puriﬁed with the clean-up RNeasy Mini
Kit (QIAGEN), the purity was assessed by spectrophotometry (ratio of absor-
bance at 260 nm/absorbance at 280 nm in water of at least 1.7 to 1.8), and the
quantity of RNA was calculated by determination of its absorbance at 260 nm
(assuming a speciﬁc absorption coefﬁcient of 0.025 ml g
1 cm
1). cDNA
synthesis was carried out with the reverse transcription system of Promega
(Promega Corp., Madison, WI) with 5 g of RNA. The internal standard was
prepared by RT-PCR and was designed to be smaller than the target amplicon
in the competitive RT-PCR. The forward primer contained an internal sequence of
bax preceded by a more upstream sequence in the gene (underlined), which corre-
sponds to the full-length bax forward primer sequence (underlined) (5-CAGCT
CTGAGCAGATCATGAAGACAGGACAGTAACATGGAGCTGCA-3), and
the sequence shown below as the reverse primer. The PCR product was sub-
jected to agarose gel electrophoresis, and the amplicon (sBax; which was used as
the internal standard) was cut and extracted by using a QIAquick gel extraction
kit (QIAGEN). The DNA was quantiﬁed by performing electrophoresis with the
MassRuler DNA ladder (Fermentas International Inc., Burlington, Ontario,
Canada). Low-range intensities were assessed by a Bio-Rad Gel Doc analyzer
operated with Quantity One software. The estimation of the Bax mRNA con-
centration was performed by mixing the reverse transcription products of the
samples with various amounts of internal standard (from 1 to 1,000 ag) and with
the primers (full-length bax sequence) 5-CAGCTCTGAGCAGATCATGAAG
ACA-3 (forward primer) and 5-GCCCATCTTCTTCCAGATGGTGAGC-3
(reverse primer) (ﬁnal primer concentrations, 0.2 M) with 0.18 mM de-
oxynucleoside triphosphate mixture in PCR buffer (7.5 mM Tris-HCl [pH 9]), 0.2
mM MgCl2,5m MK C l ,2m M( N H 4)2SO4, and 2.5 U of polymerase (BioTools
B & M Labs, S.A. Madrid, Spain). The PCR proﬁle was 95°C for 45 s, 60°C for
45 s, and 72°C for 2 min for 30 cycles, followed by termination incubation at 72°C
for 7 min. After PCR, aliquots of the reaction products were analyzed by elec-
trophoresis in a 1.8% agarose gel. The gel was then stained in electrophoresis
buffer containing 0.5 g/ml ethidium bromide and washed in 1 mM MgSO4. The
amount of mRNA was estimated by comparing the relative intensities of the
ampliﬁed internal standard and of the cDNA of interest (Bax). The relative
amounts of DNA corresponding to sBax (internal standard) and Bax were mea-
sured by using the Bio-Rad Gel Doc analyzer.
Statistical analyses. The signiﬁcance of the differences between paired values
was tested by Student’s t test (Excel 2000; Microsoft, Inc., Bellevue, WA).
Correlations were calculated by using GraphPad Prism version 4.02 for Windows
(GraphPad Software, San Diego, CA).
Materials. Dulbecco’s modiﬁcation of Eagle’s minimum essential medium and
trypsin-EDTA were purchased from Life Technologies, Paisley, United King-
dom. Gentamicin sulfate was provided as Geomycine (the branded product
registered for clinical use in Belgium) by Glaxo-SmithKline Belgium (on behalf
of Schering-Plough Corp., Kenilworth, NJ); conversion of grams to moles was
done by using a mean molecular weight of 464.4 (sulfate salt form), based on the
average contribution of the main subcomponents (C-1, 30%; C-1a, 20%; C-2,
50%) required by the European Pharmacopoeia (65). Aprotinin, HEPES,
CHAPS, PMSF, DTT, ubiquitin-aldehyde, and Z-Leu-Leu-Leu-aldehyde (MG132)
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rose beads came from Roche Diagnostics (F. Hoffmann-La Roche Ltd., Basel,
Switzerland).
RESULTS
Validation of electroporation conditions. The efﬁcacy of elec-
troporation for the delivery of nonpermeant solutes was as-
sessed by examining the penetration of trypan blue and lucifer
yellow added to the electroporation buffer. Fifteen minutes after
electroporation, 64.3%  6.5% (trypan blue) and 63.4%  6.0%
(lucifer yellow) of the cells were homogeneously stained. In par-
allel, the effective resealing of the pericellular membrane was
assessed through the measurement of the release of the cyto-
solic enzyme lactate dehydrogenase into the culture medium.
A typical value of release, recorded 15 min after electropora-
tion, was 11.3%  2.1% of the total cell content, whereas the
value was 9.1%  2.3% for nonelectroporated cells. Electro-
porated cells were also examined under an electron micro-
scope to verify the absence of alterations of the main subcel-
lular organelles and the intactness of the pericellular membrane.
No signiﬁcant difference from the control (nonelectroporated)
cells was noticed.
Morphological demonstration of apoptosis. Cells subjected
to electroporation in the presence of increasing concentrations
of gentamicin were examined 24 h after electroporation for
morphological evidence of apoptosis (DAPI staining). As
shown in Fig. 1, cells electroporated in the presence of low
concentrations of gentamicin (0.03 mM; 13.9 mg/liter) already
showed typical images of apoptosis, consisting of the fragmen-
tation and condensation of the nuclear material. These images
were similar to those seen for cells incubated with gentamicin
for 24 h but at considerably higher concentrations (3 mM; 1.39
g/liter), as described previously (61). The occurrence of apop-
tosis in cells electroporated in the presence of low concentra-
tions of gentamicin was conﬁrmed by electron microscopy,
which revealed typical images, such as the condensation of
chromatin material abutting the nuclear membrane (Fig. 2).
These cells did not show a visible alteration of their pericellular
membrane (inset of Fig. 2). Similar images were seen in the
present investigation for cells incubated with gentamicin at
high concentrations (1 to 3 mM; data not shown) and in our
previous study (12).
Quantitative analysis of apoptosis. Figure 3 shows the per-
centage of apoptotic cells (as assessed by DAPI staining)
among cells electroporated in the presence of increasing con-
centrations of gentamicin and examined after 24 h of culture in
drug-free medium in comparison with that among cells incu-
bated for 24 h with increasing concentrations of gentamicin. It
appears that the electroporated cells were about 100-fold more
sensitive to gentamicin-induced apoptosis than the incubated
cells. The frequency of apoptotic cells among the electropo-
rated cells, however, reached a maximum at 0.3 mM (139
mg/liter) and sharply declined thereafter. With high gentami-
cin concentrations, indeed, most samples showed a large pro-
portion of cells undergoing pycnotic nuclear degeneration
(characterized by highly condensed but not fragmented nu-
clear material), suggesting the occurrence of massive necrosis.
This was conﬁrmed by measurement of the release of lactate
dehydrogenase, as shown in the lower panel of Fig. 3. Cells
incubated with gentamicin did not show necrosis within the
range of concentrations investigated here (up to 3 mM [1.39
g/liter]). Yet, incubation of the cells with higher concentrations
(from 4 mM [1.85 g/liter]) caused detectable necrosis (data not
shown), as reported previously (61).
FIG. 1. Staining of nuclei of LLC-PK1 cells by DAPI. Electroporated (left panel), cells were electroporated in the absence of gentamicin (no
GEN) or in the presence of gentamicin (GEN) at the concentration shown (0.03 mM; 13.9 mg/liter) and were examined 24 h later; incubated (right
panel), cells were maintained for 24 h in the absence of gentamicin (no GEN) or in the presence of gentamicin (GEN) at the concentration shown
(3 mM; 1.39 g/liter). In the absence of gentamicin, both electroporated and incubated cells show diffuse ﬁnely reticulated staining characteristic
of the euchromatin of diploid interphase animal cells. In contrast, cells electroporated or incubated in the presence of gentamicin show typical
changes associated with apoptosis, consisting of the condensation and fragmentation of the nuclear material. A color version of this ﬁgure is
available for download at http://www.facm.ucl.ac.be/public/AAC-0897-05-Figure-1-color.jpg.
FIG. 2. Electron microscopy of LLC-PK1 cells electroporated in
the presence of 0.1 mM (46.4 mg/liter) gentamicin and examined 24 h
later. The main image shows a typical nucleus demonstrating apoptotic
features consisting of condensed and fragmented chromatin clumps
abutting the perinuclear membrane. The inset shows that the pericel-
lular membrane of that cell is intact (with many, normal-looking mi-
crovilli).
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shows the variation of the apparent cellular gentamicin content
in cells electroporated in the presence of the drug (at increas-
ing concentrations) and monitored for the next 24 h compared
with that in cells incubated with increasing concentrations of
the drug for up to 24 h (while the two processes are very
different, we present the data together since comparison of the
data is instructive). With electroporated cells (left panel of Fig.
4), there was a marked and immediate accumulation of gen-
tamicin that was proportional to its extracellular concentra-
tion, with an apparent cellular concentration to extracellular
concentration ratio of approximately 6 (see the slope of the
correlation shown in the inset of the left panel of Fig. 4). The
amount of gentamicin found to be associated with electropo-
rated cells exposed to high extracellular concentrations of gen-
tamicin (0.3 mM [139 mg/liter] or higher) quickly decreased
over the next 6 h and decreased more slowly thereafter to
reach values about 8- to 10-fold lower than the original ones
after 24 h. In contrast, the amount of gentamicin found in
cells electroporated in the presence of 0.1 mM (46.4 mg/
liter) gentamicin decreased to only about 30% of the orig-
inal amount within 24 h. No decrease was seen from cells
incubated with only 0.03 mM gentamicin (13.9 mg/liter).
This behavior was in sharp contrast to what was observed
with cells incubated with gentamicin (right panel of Fig. 4).
In accordance with our previous results (12), the uptake of
gentamicin proceeded almost linearly with time and was
proportional to the extracellular concentration (resulting in
a mean, stable clearance of 4.44 l per mg of cell protein
and per day). The apparent cellular concentration to extra-
cellular concentration ratio of gentamicin in incubated cells
was about 0.8 after 24 h (see the slope of the correlation
shown in the inset of the right panel of Fig. 4), in accordance
with the ﬁndings of our previous studies (12).
It is interesting that cells electroporated in the presence of
0.03 mM (13.9 mg/liter) gentamicin showed an apparent drug
concentration (measured after 1 h) of about 0.3 g/mg protein
and that these cells developed extensive apoptosis (16%)
within the next 24 h. By comparison, in this time frame, cells
incubated for 24 h with 3 mM gentamicin developed about
11% apoptosis, for an apparent cell gentamicin content of
about 5.4 g/mg when it was measured at 24 h.
Increase in the cell content of the proapoptotic Bax protein.
Apoptosis induced by cytotoxic agents is increasingly reported
to be associated with a larger cell content of the proapoptotic
protein Bax (4, 52, 57). In pilot studies with cells incubated
with gentamicin (2 mM), we observed a signiﬁcant increase in
the level of Bax from8ho fincubation, and this progressed
over time up to 32 h. We therefore looked for a similar in-
crease in cells electroporated in the presence of gentamicin.
Figure 5 shows that there was a marked increase in the cell
content of Bax 8 h after electroporation at extracellular gen-
tamicin concentrations of 0.03 and 0.1 mM. At 0.03 mM, this
increase (about twofold) was similar to that seen with cells
incubated for 8 h with 2 mM gentamicin. The origin of this
increase was then examined in terms of Bax overexpression
and/or decreased degradation. Competitive RT-PCR failed to
reveal signiﬁcant changes in the cell content of Bax mRNA
(data not shown). In contrast, Fig. 6 shows that the ubiquiti-
nated forms of Bax were signiﬁcantly increased in cells elec-
troporated in the presence of gentamicin as well as in cells
incubated with gentamicin, largely in parallel with the in-
creases in Bax itself.
FIG. 3. Inﬂuence of gentamicin concentration on apoptosis (upper
panel) and necrosis (lower panel) in LLC-PK1 cells. Apoptosis was
assessed by enumeration of typical apoptotic nuclei (DAPI staining;
see Fig. 1). Necrosis was assessed by measuring the release of the
cytosolic enzyme lactate dehydrogenase (LDH) in the culture medium
(shown as the percentage of the total amount in cells plus medium).
Electroporated, cells were subjected to electroporation in the presence
of gentamicin at the concentrations showed in the abcissa, returned to
gentamicin-free medium, and examined 24 h later; incubated, cells
were cultivated for 24 h in the presence of gentamicin at the concen-
trations shown on the abscissa. The 0 value on the abscissa corresponds
to cells electroporated (closed symbols) or incubated (open symbols)
in the absence of gentamicin. Values are means  standard deviations
(n  3). Statistical analysis was performed by the use of analysis of
variance, and the values of the datum points with different letters in the
electroporated cell or the incubated cell panels are signiﬁcantly differ-
ent from those of all other points in the same group (P  0.05; for
lactate dehydrogenase release [lower panel], there is no signiﬁcant
difference among any of the datum points for incubated cells); the
asterisks show the signiﬁcant differences (P  0.05) between groups
(electroporated versus incubated cells).
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The main ﬁnding of the present study is that gentamicin
causes apoptosis in LLC-PK1 cells when they are subjected to
electroporation with extracellular drug concentrations consid-
erably lower than those needed to cause apoptosis in cells
incubated with gentamicin. These concentrations (10 to 15
mg/liter) are both microbiologically and pharmacologically
meaningful (12, 61). This takes place without evidence of gross
cell damage (beyond what could be associated with apoptosis),
based on morphological data and a lack of marked lactate
dehydrogenase release. The absence of visible alterations of
intracellular organelles upon electroporation is consistent with
the fact that the effect of electric pulses on membrane perme-
ability is critically dependent on the size of the corresponding
structures. Lysosomes and mitochondria, for instance, typically
require much more severe conditions than whole cells, namely,
a 300-fold higher potential and much shorter pulse durations,
to be signiﬁcantly affected by electroporation (3).
Although considered a valid in vitro model for the study of
aminoglycoside-induced toxicity, LLC-PK1 cells accumulate
gentamicin much more slowly and less effectively than proxi-
mal tubular cells. As observed here and as discussed earlier
(12), the rate of gentamicin uptake in LLC-PK1 cells cultivated
as monolayers is indeed similar to that of validated tracers of
ﬂuid-phase pinocytosis. The situation is different in proximal
FIG. 4. Cell contents in gentamicin as a function of its extracellular concentration and time. Electroporated (left panel), cells were subjected to
electroporation in the presence of gentamicin at the concentrations indicated by the closed symbols at the top of the graphs and returned to drug-free
medium for incubation at 37°C for the times indicated on the abscissa; incubated (right panel), cells were incubated at 37°C in the presence of gentamicin
at the concentrations indicated by the open symbols at the top of the graphs for the times indicated on the abscissa. Values are means  standard
deviations (n  3). (Insets) Correlation between the apparent cellular concentration (Cc) and the extracellular concentration (Ce) measured 1 h after
electroporation for electroporated cells (left; slope, 6.3  0.5) and after 24 h for incubated cells (right; slope, 0.76  0.02).
FIG. 5. Detection of the proapoptotic protein Bax by Western blot
analysis of lysates of LLC-PK1 cells. The ﬁlms were analyzed by den-
sitometry (with measurements done in triplicate; the values shown are
means  standard deviations; when not visible, the standard deviation
bars are smaller than the minimal resolution of the graph). Electro-
porated (left panel), cells were subjected to electroporation in the
presence of gentamicin at the concentrations shown on the abscissa
and returned to drug-free medium for8ha t37°C before they were
collected and processed; incubated (right panel), cells were maintained
at 37°C for8hi nt h epresence of gentamicin at the concentrations
indicated on the abscissa. The 0 value on the abscissa corresponds to
cells electroporated (closed bars) or incubated (open bars) in the
absence of gentamicin. OD, optical density.
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cytosis because of the presence of acidic phospholipids (58)
and of a speciﬁc binding site for polybasic compounds (megalin
[45]) at the level of the brush border of proximal tubular cells.
LLC-PK1 cells, however, seem to express megalin only when
they are grown on inserts, i.e., under conditions that allow their
polarization (47). Yet, apoptosis can be unambiguously dem-
onstrated in LLC-PK1 cells grown as monolayers when the
cellular concentration of gentamicin is made similar to that
observed in the proximal tubules of animals treated with low
doses of gentamicin (11), i.e., in a 2- to 20-g/mg protein
range. In the ﬁrst analysis, it would seem to be reasonable to
assume that electroporation simply allows the initial cell con-
centration of gentamicin to immediately reach the critical cell
concentrations needed to trigger apoptosis.
There is, however, a major qualitative difference between gen-
tamicin delivery to cells by pinocytosis (ﬂuid or adsorptive) and
delivery by electroporation. Pinocytosis (in cultured cells in vitro
or in proximal tubular cells in vivo) should, indeed, direct the drug
primarily to lysosomes, as observed for impermeant solutes (5)
and for gentamicin in particular (18, 68). In contrast, the data
obtained with trypan blue and lucifer yellow indicate that elec-
troporation could allow gentamicin to directly gain access to the
cytosol. Yet, we showed that incubation of LLC-PK1 cells with
gentamicin causes a destabilization of lysosomes before the acti-
vation of the so-called apoptosis mitochondrial pathway becomes
evident (61). This led us to conclude that it is the gentamicin
leaking from lysosomes that eventually causes apoptosis in cells
incubated with this drug (61).
The role of lysosome destabilization in the initiation of the
apoptotic process was further surmised from the fact that gen-
tamicin (i) is able to permeabilize phospholipid bilayers under
conditions that mimic the lysosomal environment (61) and (ii)
has been shown, from about 10% of the total cell content, to
quickly trafﬁc through to the Golgi complex and the endoplas-
mic reticulum, from where it could be transported to the cy-
tosol and reach mitochondria (56). The higher susceptibility of
electroporated cells than incubated cells to apoptosis could
therefore result from differences in the subcellular distribution
of the bulk of the drug. Quantitative analysis based on the data
presented in Fig. 3 and 4 supports this conclusion. Cells elec-
troporated in the presence of gentamicin at 0.03 mM (13.9
mg/liter) showed an apparent drug concentration (measured
after 1 h) of about 0.3 g/mg protein, and these cells developed
extensive apoptosis (16%) within the next 24 h. In this time
frame, cells incubated for 24 h with 3 mM gentamicin develop
about 11% apoptosis, for an apparent cell gentamicin content
of about 5.4 g/mg protein when the content is measured at
24 h. Only 5 to 6% of this amount would need to be delivered
to the cytosol during the 24-h incubation period to create a
condition similar to that which is probably taking place initially
in electroporated cells. This value is close to that which has
been suggested to be diverted from the lysosomes of cells
incubated with gentamicin, based on a detailed morphological
study of its disposition in LLC-PK1 cells (56).
Such a small proportion of the total amount of gentamicin
taken up by cells could not be detected by the cell fractionation
techniques previously used to assess the intracellular fate of
gentamicin in cultured cells (68) or in the kidney cortex (18).
Our study gives no explanation for the decrease in the genta-
micin cell content from electroporated cells upon incubation,
as seen in Fig. 4. A plausible explanation for the rapid loss of
gentamicin from electroporated cells, however, could simply
be the nonimmediate closure of the pores and, for cells elec-
troporated with high concentrations of gentamicin and/or that
have taken up a large amount of the drug, the onset of necrosis
(as observed in Fig. 3). This should be studied in the future, but
the limited size of the samples (due to technical constraints
linked to the electroporation technique) will require the use of
very sensitive and reliable techniques to examine in detail the
disposition of the drug and its fate after electroporation.
With respect to the drug found to be associated with the cells
after electroporation, we also ignored the subcellular distribu-
tion and the proportion that is free. Gentamicin is known to
bind to a variety of acidic macromolecules and supramolecular
structures, which, incidentally, would explain why its concen-
tration may initially be higher in electroporated cells than in
the extracellular ﬂuid. However, binding to nontarget constit-
uents should similarly affect the drug leaking from lysosomes
and that entering cells by electroporation.
A direct effect of cytosolic gentamicin as a trigger of apop-
tosis (irrespective of its origin) is actually strongly suggested
from the observation that the cell content of the proapoptotic
protein Bax is increased in both electroporated and incubated
cells when gentamicin is present. Bax has a pivotal role in
controlling apoptosis; and an increase of its cellular content
triggers apoptosis, as observed in both cancerous and noncan-
cerous cell lines as well as in vivo, arguing for a non-cell-type-
dependent effect (13, 23, 36).
FIG. 6. Detection of the ubiquitinated forms of the proapoptotic
protein Bax by Western blot analysis of lysates of LLC-PK1 cells. Bax
was immunoprecipitated with an anti-Bax antibody, and the uniquiti-
nated proteins were revealed on the membrane with an antibody di-
rected against ubiquitinated proteins but not free ubiquitin. The ﬁlms
were analyzed by densitometry measurements made in triplicate; the
values shown are means  standard deviations; when not visible, the
standard deviation bars are smaller than the minimal resolution of
the graph). Electroporated (left panel), cells were subjected to elec-
troporation in the presence of gentamicin at the concentrations shown
on the abscissa and then returned to drug-free medium for8ha t37°C
before they were collected and processed; incubated (right panel), cells
were maintained at 37°C for8hi nt h epresence of gentamicin at the
concentrations indicated on the abscissa. The 0 value on the abscissa
corresponds to cells electroporated (closed bars) or incubated (open
bars) in the absence of gentamicin. OD, optical density.
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mitochondrial membrane (73) and to cause cytochrome c re-
lease, which ampliﬁes the apoptotic signal (31). We see here
that what differentiates electroporated cells from incubated
cells is their greater sensitivity to the increase in the amount of
Bax with respect to the gentamicin concentration. We also
know that mitochondria are involved in gentamicin-induced
apoptosis in LLC-PK1 cells when these cells are incubated with
the drug (61). We may therefore reasonably assume that what
triggers apoptosis in electroporated cells is also the increase in
the Bax content. Unfortunately, the small amount of cells that
could be subjected to electroporation has prevented us from
performing fractionation studies to demonstrate directly the
translocation of Bax and the release of cytochrome c.
As is the case for any protein, the increase in Bax content
could result from an increase in its transcription or a decrease
in its degradation, or both. The ﬁrst mechanism is unlikely,
since we did not observe signiﬁcant changes in Bax mRNA
levels. Conversely, we observed an increase in the amount of its
ubiquitinated forms. Bax is degraded by the proteasome (8, 35)
but, like other proteins, needs to be ubiquitinated before it can
be processed (speciﬁc signaling [21]). Inhibition of the protea-
some by speciﬁc inhibitors is known to cause an increase in
ubiquitinated Bax, and this was shown to slow the rate at which
Bax itself can be ubiquitinated (9, 30, 35, 50). Our observations
are consistent with such a process but do not identify the
nature of the proteasome inhibitor. Yet, a recent study showed
that gentamicin may interact directly with the  type 9 subunit
of the proteasome (22). The implications of this interaction in
terms of modulation of proteolytic activity need, however, to
be ascertained.
An apparent difﬁculty for giving to Bax the central role that
we propose, however, is that maximum apoptosis is seen with
0.3 mM gentamicin, whereas the Bax content is maximal at a
10-fold lower gentamicin concentration (0.03 mM). This may
result from the combination of three phenomena. First, apop-
tosis is not linearly related to the concentration of gentamicin.
Second, the increase in the amount of Bax with respect to the
concentration of an apoptosis-triggering agent is also not linear
(a typical example has been presented elsewhere [20]). Third,
an increase in the level of Bax precedes apoptosis, making the
two processes not necessarily linearly related. Finally, we can-
not exclude the possibility that gentamicin itself participates in
the triggering of apoptosis (through a direct interaction with
the mitochondria, once its concentration reaches a sufﬁcient
value, as has been observed in vitro [39]), causing an increase
in the level of Bax and apoptosis to become dissociated with
respect to the gentamicin concentration.
Many studies indicate that it is the ratio of the proapoptotic
Bax and the antiapoptotic Bcl-2 that is critical in the initiation
of drug-induced apoptotic cell death (75). We observed previ-
ously that Bcl-2 overexpression in LLC-PK1 cells (through
transfection) prevents gentamicin-induced apoptosis (12). We
did not examine this possibility here because (i) while Bcl-2 is
abundant in embryonic kidney and is expressed in correlation
with the apoptosis-related remodeling processes typical of this
developmental stage, its expression in adult renal cells is low
(63); and (ii) our attempts to detect Bcl-2 in the strain of
LLC-PK1 cells used here revealed only minimal expression by
Western blotting (12) or RT-PCR analysis (H. Servais, unpub-
lished data). Yet, others have clearly observed such an expres-
sion in LLC-PK1 cells and have demonstrated its role in pro-
tecting the cell from apoptosis in at least two situations of
drug-induced nephropathy (46, 74). The literature, however,
suggests that rather than Bcl-2, it is its homologue, Bcl-xL, that
may be controlling apoptosis in renal cells (37, 49). Future
work is therefore needed to better ascertain the role of Bcl-2
and its homologues in gentamicin-induced apoptosis.
Our study also revealed that electroporation in the presence
of gentamicin may cause necrosis if the drug concentration
exceeds 0.3 mM. This toxic effect is not speciﬁcally linked to
the electroporation since extensive necrosis is also observed for
cells incubated with gentamicin if its extracellular concentra-
tion exceeds 3 mM (61). It illustrates the well-known fact that
apoptosis and necrosis are two adverse effects that drugs cause
at low and high concentrations, respectively (6, 19, 70). This
explains why the cell Bax content decreases at high gentamicin
concentrations through global, necrosis-related impairment of
protein synthesis in association with the fast turnover (1 to 2 h)
of that protein (35). In the case of aminoglycosides, apoptosis
readily develops in the rat kidney cortex at low doses (11),
together with other ultrastructural and functional alterations
(for a review, see reference 69). Necrosis, however, becomes
systematically predominant at high doses (for a review, see
reference 40). The point of interest here is that necrosis could
easily be obtained when cells were exposed to gentamicin dur-
ing electroporation. As discussed earlier, this mode of delivery
bypasses the lysosomal sequestration of gentamicin seen in
incubated cells or in vivo as a result of its pinocytotic uptake.
Thus, contrary to our previous hypotheses, it is possible that
lysosomal damage (for a review, see reference 33) and necrosis
are unrelated events. The former would be directly related to
the local effects of gentamicin, such as phospholipase inhibi-
tion (32), while the latter would result from a direct effect of
gentamicin on nonlysosomal constituents. The evidence pre-
sented here as well as in previous work may even suggest that
gentamicin sequestration in lysosomes is, to some extent, pro-
tective against apoptosis and necrosis-related toxicities. The
observation that polyaspartic acid protects against gentamicin-
induced nephrotoxicity (16) by trapping the drug in lysosomes
as a nondiffusible ionic complex (28) is also consistent with the
view that the lysosomal sequestration of gentamicin is a favor-
able event as far as nonlysosomal effects are concerned. It
remains true, however, that pinocytotic uptake of aminoglyco-
sides by proximal tubular cells is the primary cause of nephro-
toxicity, since (i) mice with genetic or functional megalin de-
ﬁciency, which makes them unable to accumulate the drug in
these cells by receptor-mediated pinocytosis, are protected
against toxicity (59); and (ii) maneuvers that result in the
decreased uptake of aminoglycosides by impairing or saturat-
ing their pinocytic uptake are associated with a reduced toxicity
(for a review, see reference 40). The lysosomal accumulation of
gentamicin would therefore appear to be a double-edged phar-
macokinetic weapon for the cell. It would indeed afford pro-
tection from general cellular toxicity, as long as lysosomes
remain intact. However, it would also precipitate cell death,
once gentamicin, stored in large amounts in these organelles, is
released as a consequence of drug and phospholipid overload-
ing (33), direct permeabilization of the lysosomal membrane
(61), interference with proteins that stabilize the lysosomal
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paratus and the endoplasmic reticulum (55, 56). Protection
against gentamicin-induced nephrotoxicity in vivo could there-
fore be envisaged not only by blocking its pinocytic uptake in
cells (44) but also by preventing its release from lysosomes.
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